Mallinckrodt's FTC Settlement Seems A Blip For Acthar Blockbuster
Executive Summary
Company anticipates steady sales of its blockbuster treatment for infantile spasms and other severe conditions for many years, despite agreement to out-license a potential competitor as part of settlement with US trade commission. Settlement resolving investigation into earlier Questcor acquisition also includes $100m fine.
You may also be interested in...
MedPAC Analysis Of 'Low-Value' Medicare Treatments Spotlights Acthar
The Medicare Payment Advisory Commission’s annual 2018 report to Congress features the flip side of the recent value-based rhetoric – highlighting “low-value” Medicare purchases. The drug chosen to make that argument is Mallinckrodt’s HP Acthar Gel.
Mallinckrodt Reduces Acthar Reliance With $1.2bn Sucampo Buy
Mallinckrodt is to acquire Sucampo Pharmaceuticals for about $1.2bn. The deal brings it a short-term sales boost from Amitiza, although the constipation treatment only has a few years left before generic competition hits. Longer-term hopes lie in two Phase III products for rare diseases.
Pharma’s Pricing Debate Splinters As US Political Confrontation Looms
Drug makers are embracing different strategies on the pricing issue as the industry marches closer to a confrontation with President-Elect Trump over the cost of medicines.